The Compound at 12: The Worked-Example Stack Into Q3, and What's Next for This Briefing

Twelve issues. The arc that started with the Literature Test in Issue 1 closes here.

The point of running a 12-issue arc was not to cover 12 compounds. It was to build a decision framework an operator could carry into every protocol question that lands after this briefing ends. The framework is the deliverable. The stack below is the worked example — what twelve issues of constraint actually produces when the framework gets applied to one founder's biology.

If you read every issue and arrived at a different stack, the framework is doing its job. The point was never to copy the protocol. The point was to make better decisions about your own.

Composition. Reasoning by issue. Not a recommendation. The stack below is the worked-example output of applying the framework — each line is a decision the framework produced when the issue's selection criterion was applied.

GLP-1 axis. Tirzepatide, weekly, on the trial-pace titration ladder from Issue 6. The worked example holds at the current titration level through Q3 — body composition endpoint, not weight target. Issue 9's accumulation-mismatch argument is why the ladder is slow. Issue 6's decision tree is why tirz over reta in this phase: GI tolerance is the constraint that matters more in this worked example than the marginal weight-loss delta.

Repair stack. BPC-157 + TB-500 cycled per the Wolverine framework in Issue 5, only when an actual injury or load-cycle calls for repair. Not continuous. The Issue 5 selection criterion is inflammation and tissue context, not a standing protocol.

Growth axis. CJC-1295 + Ipamorelin, pulsatile, pre-sleep — not MK-677. Issue 7's water-retention selection criterion is the deciding variable: body-composition feedback without fluid noise. The Tier 3/4 evidence asymmetry on the CJC + Ipa stack is named and accepted in the worked example.

Cognitive layer. Selank intranasal AM, Semax pre-deep-work. The Issue 8 caveat stands: a parallel-start design cannot fully isolate the two effects. The subtraction-not-addition framing from Selank is the operationally useful piece.

Dropped from the prior stack. NMN. The Issue 10 audit is the deciding read. Circulating NAD+ rises on bloodwork. Nothing else moves in a way the Tier 1 literature would predict. Honest n=1 framing: the compound does what it says biochemically and does not produce functional change at the population level the Tier 1 evidence describes. Removed from the worked example.

Watching, not running. Kisspeptin. GHK-Cu systemic. Cagrisema when it lands. Issue 11 is why. The mechanism homework is done. The evidence tier is not where it needs to be in this worked example yet.

That is the stack. Six compounds in active rotation in the worked example, four watched, one removed. Every line item references the issue that produced the decision.

Stepping back from the stack: what twelve issues of framework produced.

Issue 1's Literature Test is the gate every compound has to pass before it gets stack consideration. NMN failed it on the functional-claim line. Cagrisema is held back from RUO channels but mechanistically pre-cleared for when it does become available. The Test is what kept the stack from sprawling.

Issue 2's COA framework is why the vendor decision is downstream of the compound decision, not coupled to it. Mass spec identity, purity certificate, batch-dated, third-party. The discipline is not optional.

Issue 3's half-life math is the most-cited piece of framework across the arc. Five issues since explicitly applied it: Issue 6 (GLP-1 family titration), Issue 7 (CJC steady-state vs. Ipamorelin pulse, MK-677 24-hour plateau), Issue 8 (Selank plasma vs. CNS-effect duration), Issue 9 (retatrutide accumulation mismatch), and the stack reasoning above. If you only read three issues of this briefing, Issue 3 is the load-bearing one.

Issue 4's n=1 protocol — pre-labs, single-variable rule, structured tracking, post-labs — is the only way to know what your specific biology does on a compound. The NMN removal happened because the protocol produced a real answer. Without the protocol, you get a vibe.

The framework is portable. It applies to compounds the briefing did not cover, to protocols I did not run, and to the next decade of compounds the literature has not produced yet. That portability is the reason the arc was built this way.

The first arc was Foundation, Application, Edge. Twelve issues, framework-first, worked examples after.

The second arc starts in two weeks. Working title: Protocols in Practice. Issues 13 through 24. The shift is from framework to operator-grade implementation: full multi-week protocol walkthroughs, blood panel sequences, the female-cycle-aware peptide protocol the original brief flagged, the Khavinson bioregulator file, the 503(b) regulatory beat, and a recurring vendor-audit slot using the Issue 2 COA framework on real batches.

The cadence stays the same: Sunday 9am ET, one email a week, five-to-seven minutes to read.

One signal-temperature check: a small group of subscribers has asked about a paid tier — deeper protocols, the unpublished n=1 data, a quarterly office-hours call. I am not announcing one. I am listening for whether enough operators want it that building it makes sense. If you have a strong view, reply to this email. The reply goes to me, not a queue.

Last item. The lead magnet is being refreshed. The 2026 Peptide Stack Map was the original. The H2 refresh — Compound Stack Brief 2026 H2 — incorporates the Issue 6 GLP-1 decision tree, the Issue 7 pulse-vs-plateau matrix, the Issue 9 titration ladder, and the Issue 11 frontier compounds. Existing subscribers get the refresh in early August at no charge. New subscribers get the H2 version on opt-in.

Twelve issues of framework, applied to one founder's biology, produced a six-compound active stack with one Issue-10-driven removal and four watched compounds in queue. The stack is the worked example. The framework is the deliverable. Issue 3's half-life math is the single most-cited piece. The Issue 1 Literature Test is the gate. The Issue 4 n=1 protocol is the only way to know what your biology actually does.

The first arc closes here. The second arc — Protocols in Practice — opens in two weeks. Same Sunday, same format. Different altitude.

See you Sunday.

Colby

For research use only. Not medical advice. Compounds discussed are sold for research purposes; nothing here is a recommendation to use them on humans or animals. The publisher of The Compound has a financial interest in heroxbio.com, an RUO peptide vendor; this relationship may influence which compounds are covered. See the About page for full disclosure.